Translating cancer biology into medicines

NASDAQ CYCC
BIO CEO Investor Conference
February 12, 2019

Disclaimer

This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. The information in this presentation is current as of this date. Cyclacel does not take any responsibility to update such information.

Cyclacel Overview

- Apply deep understanding of cell cycle biology to disrupt cancer
    - **resistance**
    - **DNA repair** or evasion
- Precision medicine strategy targeting
    - **Mcl-1** in leukemias (Phase 1)
    - **BRCA1/2** in breast cancer (Phase 1/2)
- Experienced management; estimated capital through Q2 2020

Clinical Stage Value Drivers

CYC065

- CDK inhibitor with proof of mechanism (down-regulation of Mcl-1) in humans
- 2L venetoclax combination in leukemias (CLL, AML)

Sapacitabine

- Oral nucleoside analogue, unique DNA damage response mechanism for BRCA +ve patients
- 2L olaparib combination in BRCA +ve breast cancer

CYC140

- PLK inhibitor with compelling preclinical data in liquid & solid cancers

Addressing Large Markets

CLL 2L

- 21k US incidence; majority on ibrutinib (BTKi)
- CYC065 venetoclax (1L with ibrutinib or 2L)

AML elderly unfit for chemotherapy

- ~16k US incidence; venetoclax+HMA (aza or dec)
- CYC065 venetoclax combination

BRCA +ve Breast Cancer

- ~11-15k US incidence; olaparib or other PARPi
- sapa olaparib combination

Indication Rationale: 2L CLL (post BTKi)

1L US incidence 21,000; nearly all survivors receive 2L

Venetoclax does not ↓ Mcl-1

“Double-Hit” strategy to suppress Bcl-2 + Mcl-1

Preclinical evidence of synergy for venetoclax + CYC065*

CYC065 1st CDKi to durably suppress ↓ Mcl-1 in patients

CYC065 + venetoclax Ph 1b study FPI achieved

** Source: Chen et al AACR 2018 Abs 5095; Cyclacel data on file.*

CYC065 First in Human Phase 1 Part 1 Data

n=26 heavily pretreated patients with advanced solid tumors (13 in DL6 cohort RP2D)

- Durable **Mcl-1 suppression** >24h after single dose in 11/13 DL6 patients
- Anticancer activity in 6/13 patients (5 at RP2D)

** Source: Cyclacel data on file.*

CYC065 First in Human Phase 1 part 1 Activity



‡ *no information; * complex deletions/gains. High copy gains shown in bold.*

Summary:

- **20/26 patients evaluable for response per RECIST 1.1**
- **11/20 patients achieved stable disease (SD)**
- **6/11 patients achieved SD for 4+ cycles**

Do, Khanh T., et al, AACR Annual Meeting 2018.

AACR American Association for Cancer Research

CDK Inhibitor Landscape

CDK4/6 isoform

palbociclib (PFE), ribociclib (NVS), abemaciclib (LLY) Approved in combination with letrozole for ER +ve Her2 -ve advanced or met BC

trilaciclib (GTHX) Ph2

CDK2/9 transcriptional isoforms

CYC065 (CDK2/9, CYCC) Ph1 data

atuveciclib BAY1143572 (CDK9, BAY) Ph1 data

AZD4573 (CDK9, AZN) Ph1 ongoing

Other (pan CDK or selective):

flavopiridol/alvocidib (pan CDK, SUM) Ph2

dinaciclib (pan CDK, MRK) Ph3 terminated

voruciclib (CDK4/6/9, MEIP) Ph1 data

SY1365 (CDK7, SYRS) Ph1 data

Mcl-1 inhibitors: S64315 (Ph1b ven combo AML); AMG176 (FiH); AZD5991 (FiH).

** Source: Cyclacel data on file.*

Indication Rationale: HRD Breast Cancer

7-10% of all breast cancers are HR deficient*

Preclinical evidence of synergy for PARPi + sapacitabine*

Efficacy: durable, multi-year, CR, PR, SD in BRCA +ve breast, ovarian and pancreatic cancers (n=76, ASCO 2016)

Oral combination of **olaparib (Lynparza®) + sapacitabine**

Dana Farber IST ongoing (AstraZeneca/Cyclacel clinical supply)

** Source: Heeke A, et al, ASCO 2017. Liu et al Mol Cancer Ther 2016 16 2302; Cyclacel data on file. Lynparza® is a registered trademark of AstraZeneca.*

Sapacitabine & Seliciclib Ph 1 BRCA+ve Benefit*



PRESENTED AT: ASCO ANNUAL MEETING '16

Presented by: Sara M. Tolaney, MD, MPH

** Source: Tolaney S et al, JCO 34, 2016 (suppl; abs. 2503).*

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Sapacitabine in AML (SEAMLESS Ph 3 data)

Optionality from potential regulatory submission

- ✓ Increase in median OS (primary endpoint) did not reach stat. sig.
- ✓ Doubling of CR rate (secondary endpoint)
- ✓ Improved median OS in large (2/3 of study) prospectively defined subgroup based on WBC level
- ✓ Oral presentation at ASH Annual Meeting 2017
- ✓ National regulatory consultations in various EU countries
- ▪ EU regulatory consultations to determine submissibility

Source: Cyclacel press releases and data on file.

MD Anderson-Cyclacel Alliance

- Up to 170 patients with single agent or combinations of: CYC065, CYC140, sapacitabine
- Risk Sharing: MDACC assumes patient costs; Cyclacel supplies drugs and limited support
- Payments to MDACC upon First Commercial Sale in indications studied

Financial Position & Capitalization

September 30, 2018 cash & cash equivalents: $19.0m [1]

Operating cash burn (excludes non-cash items)

- ✓ 2015: ~ $14.5m annual [1]
- ✓ 2016: ~ $10.1m annual [1]
- ✓ 2017: ~ $7.5m annual [1]
- ▪ 2018: ~ $9.4m annual [2]

Fully diluted shares: ~ 20.0 million [1,3]

No debt

1. *10 K, 10 Q*
2. *Company estimate*
3. *Common stock outstanding 12.0m*

Key Milestones

- CYC065 + venetoclax Ph 1 data in R/R CLL & AML
- Evaluate bioequivalence of oral CYC065 to i.v. formulation
- Data from Ph 1 extension study of sapacitabine-based regimen in BRCA mutant breast cancer
- Sapacitabine + olaparib combination Ph 1b/2 IST data in BRCA +ve patients with breast cancer
- CYC140 Phase 1 First-in-Human study data
- Determine regulatory submissibility of sapacitabine in AML

Investment Thesis

- Clinical stage, state-of the-art oncology programs
- Targeting molecularly-defined patient populations
- Overcome cancer cell resistance & DNA repair
- CDK inhibitors: validated drug class
- Competitively positioned
- Significant market opportunities



THANK YOU

Cyclacel Pharmaceuticals, Inc.

200 Connell Drive #1500
Berkeley Heights, NJ 07922
+1 (908) 517 7330

Contact: ir@cyclacel.com